EU drug watchdog reviews Celltrion's COVID-19 antibody treatment

Celltrion

24/02/2021 15:17

Feb 24 (Reuters) - Europe's drug regulator said on Wednesday
it had started a real-time review of South Korean drugmaker
Celltrion's  068270.KS  experimental COVID-19 antibody-based
treatment, regdanvimab.
    The European Medicines Agency said its human medicines
committee was assessing the first set of data it received from
animal studies and human clinical trials, and will continue to
study them as more data was submitted. (https://bit.ly/3dHpXlr)
         

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by
Shinjini Ganguli)
 ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793 ;))